cancer
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Microbiomepost discussed with Lorella Tripodi, University Federico II of Naples, about the research she is working with her colleagues.
Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology, which provides greater…
First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform –
The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…
The findings of a recent study suggest that tilimycin-producing bacteria can cause genetic mutations in the colon and increase a person’s susceptibility to disease.
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.
The findings of a new study suggest that the microbial metabolite 3-IAA could help to treat PDAC.
